As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
15 Analysts have issued a Olema Pharmaceuticals Inc forecast:
15 Analysts have issued a Olema Pharmaceuticals Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -157 -157 |
29%
29%
|
|
| EBIT (Operating Income) EBIT | -157 -157 |
29%
29%
|
|
| Net Profit | -142 -142 |
30%
30%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
| Head office | United States |
| CEO | Sean Bohen |
| Employees | 102 |
| Founded | 2006 |
| Website | olema.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


